{"denoms":[{"counts":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"249"},{"groupId":"BG002","value":"250"},{"groupId":"BG003","value":"748"}],"units":"Participants"}],"groups":[{"description":"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nFrom Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks.","id":"BG000","title":"Placebo + Methotrexate"},{"description":"Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nSubsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6","id":"BG001","title":"Rituximab (0.5 g x 2) + Methotrexate"},{"description":"Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nSubsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6","id":"BG002","title":"Rituximab (1.0 g x 2) + Methotrexate"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.692","value":"48.06"},{"groupId":"BG001","spread":"13.391","value":"47.87"},{"groupId":"BG002","spread":"13.324","value":"47.89"},{"groupId":"BG003","spread":"13.136","value":"47.94"}]}]}],"description":"Intent-to-treat population","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"192"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"212"},{"groupId":"BG003","value":"607"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"141"}],"title":"Male"}]}],"description":"Intent-to-treat population","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}